−1.89USD
−53.47 MUSD
20.63 M
About Immuneering Corporation
Sector
CEO
Benjamin J. Zeskind
Headquarters
Cambridge
Website
Employees (FY)
68
Founded
2008
ISIN
US45254E1073
FIGI
BBG009QXJQS1
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMRX is 1.77 USD — it has decreased by 4.84% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Immuneering Corporation stocks are traded under the ticker IMRX.
Immuneering Corporation is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
IMRX stock is 7.39% volatile and has beta coefficient of 4.26. Check out the list of the most volatile stocks — is Immuneering Corporation there?
One year price forecast for Immuneering Corporation has a max estimate of 25.00 USD and a min estimate of 3.00 USD.
IMRX earnings for the last quarter are −0.43 USD per share, whereas the estimation was −0.49 USD resulting in a 12.02% surprise. The estimated earnings for the next quarter are −0.46 USD per share. See more details about Immuneering Corporation earnings.
Immuneering Corporation revenue for the last quarter amounts to 456.00 USD despite the estimated figure of 60.00 K USD. In the next quarter revenue is expected to reach 8.33 K USD.
Yes, you can track Immuneering Corporation financials in yearly and quarterly reports right on TradingView.
IMRX stock has fallen by 13.66% compared to the previous week, the month change is a 30.86% fall, over the last year Immuneering Corporation has showed a 87.53% decrease.
IMRX net income for the last quarter is −15.08 M USD, while the quarter before that showed −12.60 M USD of net income which accounts for −19.76% change. Track more Immuneering Corporation financial stats to get the full picture.
Today Immuneering Corporation has the market capitalization of 51.83 M, it has decreased by 15.20% over the last week.
No, IMRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Immuneering Corporation stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 68.00 employees. See our rating of the largest employees — is Immuneering Corporation on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Immuneering Corporation technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Immuneering Corporation stock shows the strong sell signal. See more of Immuneering Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Immuneering Corporation future price: according to them, IMRX price has a max estimate of 25.00 USD and a min estimate of 3.00 USD. Read a more detailed Immuneering Corporation forecast: see what analysts think of Immuneering Corporation and suggest that you do with its stocks.